Ginkgo Bioworks Holdings, Inc. (DNA): R&D Expense
$243.77M
Year ended 2025-12-31
$215.61M
Trailing 12 months to 2026-06-30
-38.6%
3-year compound annual growth
+8.8%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $243.77M | -42.5% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $424.06M | -27.0% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $580.62M | -44.8% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $1.05B | -8.4% | 2025-02-25, From 2022-01-01 |
| 2021-12-31 | $1.15B | +619.6% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $159.77M | +65.9% | 2023-03-13, From 2020-01-01 |
| 2019-12-31 | $96.30M | n/a | 2022-03-29, From 2019-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Ginkgo Bioworks Holdings, Inc. (DNA) | 2025-12-31 | $243.77M | -42.5% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $228.30M | +9.5% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $149.06M | +17.8% |
| Beam Therapeutics Inc. (BEAM) | 2025-12-31 | $409.62M | +11.4% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $141.50M | +16.4% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $201.58M | +171.6% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $37.45M | -75.3% |
| Agenus Inc (AGEN) | 2025-12-31 | $79.34M | -49.0% |
| ImmunityBio, Inc. (IBRX) | 2024-12-31 | $190.14M | -18.2% |
Compare DNA, RGNX, ADAPY, BEAM side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗